Document is current
Any future updates will be listed below
-
Authors
Gabriel, Walter https://orcid.org/0000-0003-0192-4005
Sazonova, Yana https://orcid.org/0000-0001-5192-5669
Kulchynska, Roksolana https://orcid.org/0000-0003-0985-0880
LaMonaca, Katherine
Salyuk, Tatiana
Smyrnov, Pavlo
Altice, Frederick L. https://orcid.org/0000-0002-7860-693X
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA043125, R01 DA029910, R01 DA033679, R01 DA045384)
- License Information
-
More Information
Article History
Accepted: 23 February 2024
First Online: 24 June 2024
Declarations
:
: Analysis of the IBBS was approved by the institutional review board (IRB) at the Ukrainian Institute on Public Health Policy (UIPHP; Kiev, Ukraine). This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes. This analysis of secondary data was approved by Yale University (New Haven, USA) and the UIPHP.
: All participants consented to participate.
: FLA is part of the speaker’s bureau for Gilead Sciences and has advisory board membership in Gilead, AbbVie, and Merck. This research was supported by the NIH, NIDA, NIAAA, FIC, SAMHSA, HRSA, Gilead Foundation, and Merck.
: The findings and conclusions in this paper are those of the authors and do not necessarily represent the official positions of the funding agencies.
